Aptamer Group introduces novel biomarker discovery service
Accelerated platform delivers validated biomarkers with ready-to-use Optimer ligands in months rather than years
Accelerated platform delivers validated biomarkers with ready-to-use Optimer ligands in months rather than years
The bottlenecks of manual ELISA are well known, but modern liquid handling tools offer a practical way to fix them
Collaboration leverages advanced simulation and regulatory expertise to develop decision frameworks for interim overall survival analysis in oncology clinical trials
New range of StarBright™ Dyes developed specifically for spectral flow cytometry provide greater flexibility in immunology research
CAL101 is a first-in-class monoclonal antibody that neutralises the S100A4 protein, which is an upstream driver and amplifier of the multiple pro-fibrotic pathways active in IPF
Learn how CancerTools.org is rewriting how cancer research tools move from lab benches to scientists around the world, and how the profits are put straight back into fighting cancer
MaxCyte’s Flow Electroporation technology and ExPERT platform to support the development of Adicet’s gamma delta T cell therapy gene edited programs
The MosaiQ instrument is a next-generation, continuous random-access immunoassay platform offering labs automation, simple workflows, fast, multiplexed results and actionable insights for complex-to-diagnose conditions
As cell line development (CLD) programs grow in complexity and scale, with increasing demands for speed, data quality, and adaptability, it is essential to choose the right analytical tools that will future-proof your workflow.
Guest editorial by Dale Powner, Country Manager for the UK, Ireland and Nordics at Binding Site, part of Thermo Fisher Scientific